Glucagon-like peptide-1 and gastric inhibitory polypeptide: New advances

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 23, Issue 1, 2016, Pages 23-27

  Gallwitz, Baptist ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Gastric inhibitory polypeptide; Glucagon like peptide 1; Incretins; Type 2 diabetes

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; INSULIN;

BARIATRIC SURGERY; BONE MASS; BONE STRUCTURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REMISSION; REVIEW; WEIGHT REDUCTION; DIABETES MELLITUS, TYPE 2; METABOLISM;

DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS;

EID: 84952334347     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000217     Document Type: Review

References (20)

1. Creutzfeldt W. The incretin concept today. Diabetologia 1979; 16:75-85.
2. Holst JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 1994; 107:1848-1855.
3. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (noninsulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
4. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (noninsulin-dependent) diabetic patients. Diabetologia 1993; 36:741-744.
5. Gallwitz B. Extra-pancreatic effects of incretin-based therapies. Endocrine 2014; 47:360-371.
6. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-149.
7. Meek CL, Lewis HB, Reimann F, et al. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides 2015. [Epub ahead of print]
8. Yousseif A, Emmanuel J, Karra E, et al. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in nondiabetic humans. Obes Surg 2014; 24:241-252.
9. Svendsen B, Holst JJ. Regulation of gut hormone secretion. Studies using isolated perfused intestines. Peptides 2015. [Epub ahead of print]
10. Gallwitz B, Rosenstock J, Patel S, et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial. Diabetes Obes Metab 2015; 17:276-284.
11. Tella SH, Rendell MS. DPP-4 inhibitors: focus on safety. Expert Opin Drug Saf 2015; 14:127-140.
12. Gallwitz B, Thiemann S, Wö rle HJ, Marx N. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the activecomparator CAROLINA1 trial. Dtsch Med Wochenschr 2015; 140:831-834.
13. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373:232-242.
14. Dungan KM, Raz I, Skrivanek Z, et al. Achieving the composite endpoint of HbA1c<7.0%, no weight gain, and no hypoglycaemia in the once weekly dulaglutide AWARD program. Diabetes Obes Metab 2015. [Epub ahead of print]
15. Rankin W, Wittert G. Antiobesity drugs. Curr Opin Lipidol 2015. [Epub ahead of print]
16. RodbardHW,Buse JB,WooV, et al.Benefits ofcombination of insulindegludec and liraglutide (IDegLira) are independent of baseline HbA1c and duration of type 2 diabetes. Diabetes Obes Metab 2015. [Epub ahead of print]
17. Mace OJ, Tehan B, Marshall F. Pharmacology and physiology of gastrointestinal enteroendocrine cells. Pharmacol Res Perspect 2015; 3:e00155.
18. Meier JJ, Nauck MA. Incretin-based therapies: where will we be 50 years from now? Diabetologia 2015; 58:1745-1750.
19. Mabilleau G. Incretins and bone: friend or foe? Curr Opin Pharmacol 2015; 22:72-78.
20. Torekov SS, Harsløf T, Rejnmark L, et al. A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk. J Clin Endocrinol Metab 2014; 99:E729-E733.